Sera Prognostics AI Stock Analysis
Want to see SERA full AI Analyst Report?
Sera Prognostics (SERA) AI Stock Analysis
Sera Prognostics
(NASDAQ:SERA)
The score is held back primarily by weak financial performance (very small revenue base, heavy losses, and sustained cash burn). Offsetting that, the latest earnings call described strong commercialization momentum and meaningful reimbursement progress with Medicaid coverage in two states plus a stated cash runway into FY2029. Technicals and valuation are neutral-to-weak, with shares trading below key moving averages and a negative P/E reflecting lack of profitability.
Sera Prognostics (SERA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $77.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 26.60K
- Price to Earnings (P/E)
- -2.9
- Beta (1Y)
- 1.48
- Revenue Growth
- 1.05%
- EPS Growth
- 13.67%
- Country
- US
- Employees
- 72
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Sera Prognostics Business Overview & Revenue Model
Company Description
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay spe...
Sera Prognostics Earnings Call Summary
The call was strongly positive, with substantial increases in ordering physicians and test volume, Medicaid coverage established in Illinois and Florida, expanding commercial and payer engagement, strengthening clinical and health economic evidence, and a stated cash runway into fiscal year 2029. The main challenges were lower third-quarter ASPs caused by a low- or non-reimbursed patient mix and the 12-month to 18-month timeframe typically required to move providers toward broad adoption. Management characterized the company as transitioning into commercialization with significant work still ahead.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Sera expects to pursue CE Mark approval for PreTRM Global in 2027, publish its PRIME health economic analysis in the fourth quarter, and see flat or down operating expenses in 2027 while significantly increasing the size of its commercial team; it believes it has sufficient cash to fund operations into fiscal year 2029. Management expects meaningful increases in product traction next calendar year, especially as it transitions to the second half of 2027, and is hoping at least 1 or 2 additional states will enact Medicaid coverage in fiscal year 2027. In Illinois and Florida, management is hoping to achieve low single-digits percentage penetration in each state in the first year and quickly accelerating afterwards; at, let's say, 20%, 30% of each state, revenue could be in tens of millions of dollars.
Sera Prognostics Financial Statement Overview
Summary
Financials are weak overall: revenue is very small and volatile, gross profit is negative, and losses remain large (TTM EBIT about -$37M; net loss about -$33M). Cash burn is persistent (TTM operating cash flow about -$28.5M; free cash flow about -$29.0M), implying ongoing funding needs. The main offset is modest leverage (debt ~ $3.0M vs. equity ~ $52M), though equity has declined materially over time.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 96.00K | 81.00K | 77.00K | 306.00K | 268.00K | 82.00K |
| Gross Profit | -99.00K | -83.00K | -5,000 | 96.00K | 75.00K | 45.00K |
| EBITDA | -32.65M | -30.98M | -32.04M | -35.29M | -43.37M | -33.60M |
| Net Income | -33.47M | -31.93M | -32.90M | -36.24M | -44.19M | -35.01M |
Balance Sheet | ||||||
| Total Assets | 79.98M | 101.93M | 72.58M | 95.44M | 116.33M | 147.03M |
| Cash, Cash Equivalents and Short-Term Investments | 44.09M | 39.20M | 46.24M | 49.08M | 82.70M | 105.11M |
| Total Debt | 3.27M | 2.34M | 840.00K | 1.86M | 2.83M | 128.00K |
| Total Liabilities | 27.54M | 26.52M | 24.77M | 25.28M | 17.39M | 8.46M |
| Stockholders Equity | 52.44M | 75.41M | 47.80M | 70.16M | 98.94M | 138.56M |
Cash Flow | ||||||
| Free Cash Flow | -28.99M | -26.35M | -15.29M | -27.32M | -35.40M | -32.94M |
| Operating Cash Flow | -28.50M | -25.62M | -14.19M | -27.19M | -34.61M | -31.64M |
| Investing Cash Flow | 28.11M | -28.50M | 11.74M | 438.00K | 5.55M | -82.56M |
| Financing Cash Flow | 301.00K | 54.03M | 2.61M | 752.00K | 5,000 | 159.59M |
Sera Prognostics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SERA, the sentiment is Negative. The current price of 2.00 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.04, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.86 is Neutral, neither overbought nor oversold. The STOCH value of 23.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SERA.
Sera Prognostics Risk Analysis
Sera Prognostics disclosed 73 risk factors in its most recent earnings report. Sera Prognostics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSera Prognostics Peers Comparison
Overall Rating
SERA53Neutral
BNR52Neutral
ACRS48Neutral
PRE47Neutral
BDSX44Neutral
VNRX44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 53Neutral | $79.54M | -2.90 | -52.54% | ― | 1.05% | 13.67% | |
| 52Neutral | $131.48M | -1.31 | -12.97% | ― | -3.65% | 51.30% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $536.11M | -5.75 | -59.20% | ― | -59.34% | 57.30% | |
| 47Neutral | $276.59M | -3.90 | -49.17% | ― | 182.05% | -5.43% | |
| 44Neutral | $98.47M | -3.24 | -442.34% | ― | 31.23% | 48.56% | |
| 44Neutral | $6.81M | -0.06 | 77.30% | ― | 134.01% | 32.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SERA | Sera Prognostics, Inc. | 2.00 | -1.20 | -37.50% | |
| VNRX | VolitionRX Ltd. | 0.19 | -6.37 | -97.13% | |
| ACRS | Aclaris Therapeutics Inc. | 3.38 | 0.92 | 37.40% | |
| BNR | Burning Rock Biotech Ltd. | 12.50 | -3.53 | -22.02% | |
| BDSX | Biodesix, Inc. | 8.88 | 1.98 | 28.70% | |
| PRE | Prenetics Group Limited | 16.33 | 3.62 | 28.48% |
Sera Prognostics Corporate Events
Sera Prognostics Announces CFO Transition and Succession Plan
PositiveOn August 14, 2026, Sera Prognostics’ board appointed Scott Gleason as Chief Financial Officer and Treasurer, effective August 31, 2026, marking a planned leadership transition in the company’s finance organization. Gleason, a 47-year-old diagnostics...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
